Suven Secures a Product Patent in Canada

Suven Life Sciences Ltd has been granted one product patent from Canada (2907620) corresponding to the new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases and this patent is valid through 2033. The granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, narcolepsy, Parkinson, and schizophrenia respectively.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”

Venkat Jasti
CEO,
Suven Life Sciences